Share This Page
Drug Price Trends for BYDUREON
✉ Email this page to a colleague
Average Pharmacy Cost for BYDUREON
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| BYDUREON BCISE 2 MG AUTOINJECT | 00310-6540-04 | 234.22034 | ML | 2025-04-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for BYDUREON
What is the Market Size and Growth Potential for BYDUREON?
BYDUREON (exenatide extended-release) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for type 2 diabetes management. The global diabetes therapeutics market was valued at approximately $57 billion in 2022[1] with an expected compound annual growth rate (CAGR) of 7% through 2027[2].
Key drivers:
- Rising prevalence of type 2 diabetes; estimated 537 million adults worldwide in 2021[3].
- Increasing adoption of injectable therapies, including GLP-1 receptor agonists.
- Growing awareness and reimbursement coverage for diabetes treatments.
BYDUREON holds a significant share within GLP-1 class drugs, with rapid market penetration since its launch in 2014.
How Does the Competitive Landscape Affect BYDUREON's Market Position?
Major competitors include:
- Novo Nordisk's Ozempic (semaglutide)
- Lilly’s Trulicity (dulaglutide)
- Sanofi’s Adlyxin (lixisenatide)
Ovulation of market share favors drugs with longer dosing intervals and proven cardiovascular benefits. Ozempic and Trulicity dominate due to FDA-approved cardiovascular risk reduction data and weekly dosing.
Market share estimates (2022):
| Drug | Estimated Market Share | Dosing Frequency | Notable Advantages |
|---|---|---|---|
| Ozempic | 40% | Weekly | Proven cardiovascular risk reduction |
| Trulicity | 30% | Weekly | Wide payer coverage |
| BYDUREON | 20% | Weekly | First extended-release injectable |
| Others | 10% | Variable | Various advantages, lesser share |
BYDUREON's niche focuses on patients preferring a longer-acting injection with an established safety profile.
What Are the Price Trends and Projections for BYDUREON?
Current Pricing (as of 2023)
- Wholesale Acquisition Cost (WAC): approximately $850–$950 per 4-week supply.
- Average out-of-pocket costs vary based on insurance, typically $30–$60.
Historical Pricing Trends
- Prices increased marginally (~2–3%) annually from 2018 to 2022.
- Reimbursement dynamics influenced by payer negotiations and manufacturer discounts.
Price Projections (2024–2028)
Considering patent protections, market share retention, and competitive pressure:
- Price stabilization expected at $850–$1,000 per 4-week supply.
- Potential for slight decrease (~5%) if generic or biosimilar competition emerges from related drug classes.
Factors influencing projections:
- Patent expiration scheduled for 2026[4].
- Adoption of biosimilar GLP-1 therapies, which could induce price competition.
- Expansion into cardiovascular indications might justify premium pricing.
How Will Regulatory and Policy Changes Impact Market and Pricing?
Regulatory approvals for new indications can enhance BYDUREON’s market size. FDA approving cardiovascular risk reduction in specific patient groups increased sales of competing drugs, indirectly benefiting BYDUREON’s positioning.
Policy shifts favoring value-based care, including formulary restrictions or prior authorization requirements, could constrain rapid price increases but also limit market access for some payer segments.
Summary of Financial Outlook
Assessments based on current market data, competitive positioning, and patent lifecycle suggest:
- Market share retention primarily through differentiation and clinical data.
- Stable pricing with minor potential for reduction from biosimilar entry.
- Revenue growth driven by increasing diabetes prevalence and expanded indications.
Key Takeaways
- BYDUREON operates within a $57 billion global diabetes market expected to grow at 7% CAGR through 2027.
- Its market share (~20%) positions it as a niche player alongside dominant competitors.
- Pricing is currently stable at around $850–$950 per 4-week supply, with slight downward pressure likely after patent expiry in 2026.
- Competitive dynamics, including biosimilar entries and new indications, will shape future pricing strategies.
- Regulatory decisions and healthcare policies will influence access and reimbursement, impacting revenue potential.
FAQs
1. When will BYDUREON's patent expire?
Expected patent expiration is in 2026, opening market opportunities for biosimilar competitors.
2. What factors could significantly influence BYDUREON’s market share?
Introduction of biosimilars, new FDA-approved indications, and comparative clinical data influencing payer preferences.
3. How does BYDUREON compare price-wise to its competitors?
It is priced slightly higher than Trulicity but lower than Ozempic at roughly $850–$950 per 4-week supply.
4. Are there upcoming regulatory approvals that could impact BYDUREON?
Potential new indications for cardiovascular benefits or device improvements could enhance its market position.
5. What is the outlook for biosimilar entry affecting prices?
Biosimilars are expected post-2026, which could lead to a 15-25% price reduction across the class.
References
[1] GlobalData. (2022). Diabetes Therapeutics Market Report.
[2] MarketsandMarkets. (2022). Diabetes Care Market Forecast.
[3] International Diabetes Federation. (2021). IDF Diabetes Atlas.
[4] FDA. (2022). Patent and exclusivity data for GLP-1 receptor agonists.
More… ↓
